Natco Pharma has received approval for Covid 19 drug molnupiravir capsules 200 mg. for Indian market, which will be sold under brand name Molnunat
The current annual U.S. market for prazosin hydrochloride 1mg, 2mg, 5mg strengths is approximately US $ 54 million, according to IQVIA/IMS Health
The Subject Expert Committee (SEC), on Covid-19 of the Central Drugs Standard Control Organisation (CDSCO) on Monday recommended granting permission to manufacture and market anti-Covid pill molnupiravir for restricted emergency use
The company will market it under the brand name Molflu
The company has developed the API in house at its R&D center in Hyderabad
The authorization provides an additional treatment option against the Covid-19 virus in the form of a pill that can be taken orally
The NMPA approval is based on the positive data of GEMSTONE-302 study, a multi-center, randomized, double-blind, phase III study that evaluated the efficacy and safety of Cejemly or placebo in combination with chemotherapy in first-line stage IV NSCLC patients
Effectiveness of Covaxin against the Omicron variant is currently being studied
It is a novel oral NLRP3 inflammasome inhibitor
The group now has 325 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.
Subscribe To Our Newsletter & Stay Updated
